Literature DB >> 21686385

Glioblastoma in a boy with fragile X: an unusual case of neuroprotection.

R Kalkunte1, D Macarthur, R Morton.   

Abstract

Glioblastomas in children usually occur in the brainstem and are often untreatable and associated with an extremely poor prognosis. Such tumours may however occur in supratentorial locations more typically associated with adult gliomas, where the outcome is more variable, but still poor. This report describes the case of a boy with fragile X who also developed an inoperable midbrain glioblastoma, but who has survived 8 years after diagnosis.

Entities:  

Year:  2009        PMID: 21686385      PMCID: PMC3027504          DOI: 10.1136/bcr.11.2008.1261

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  3 in total

1.  Astrocytoma in children: 14 years' experience at Stanford University Medical Center.

Authors:  S Y Woo; S S Donaldson; R S Cox
Journal:  J Clin Oncol       Date:  1988-06       Impact factor: 44.544

2.  Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945.

Authors:  J H Wisoff; J M Boyett; M S Berger; C Brant; H Li; A J Yates; P McGuire-Cullen; P A Turski; L N Sutton; J C Allen; R J Packer; J L Finlay
Journal:  J Neurosurg       Date:  1998-07       Impact factor: 5.115

3.  Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost.

Authors:  P K Sneed; M D Prados; M W McDermott; D A Larson; M K Malec; K R Lamborn; R L Davis; K A Weaver; W M Wara; T L Phillips
Journal:  Neurosurgery       Date:  1995-05       Impact factor: 4.654

  3 in total
  1 in total

1.  MiR-323a-3p acts as a tumor suppressor by suppressing FMR1 and predicts better esophageal squamous cell carcinoma outcome.

Authors:  Yu Men; Yirui Zhai; Lihong Wu; Lipin Liu; Wenjue Zhang; Wei Jiang; Nan Bi; Yongmei Song; Zhouguang Hui; Luhua Wang
Journal:  Cancer Cell Int       Date:  2022-03-29       Impact factor: 5.722

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.